SAMRAT PHARMACHEM
|
|
BOM : 530125     NSE :      | |
LT :  
    Long Term Analysis
Fundamentals : Average
Valuation : Bad [Stock is Expensive] Debt : Low |
Updated: |
ST :  
    Short Term Analysis
Quarterly Earnings Trend : Upward
Price Momentum : Downward Pledged Shares : NA |
Dec 06,2024 |
Price(EOD): ₹ 405.35
This is the End-of-Day (EOD) Stock Price updated daily by 7 pm IST.
|
Pharmaceuticals & Drugs |
MCap: ₹ 125.66 Cr |
Industry Peers & Returns | 1W | 1M | 1Y |
SAMRAT PHARMACHEM | 1.3% | -15.2% | 14.5% |
SUN PHARMACEUTICAL INDUSTRIES | -0.2% | 0.1% | 47% |
CIPLA | -2% | -7.7% | 23.2% |
DR REDDYS LABORATORIES | 2.6% | -1.5% | 7.9% |
ZYDUS LIFESCIENCES | 2.1% | 0.6% | 54.5% |
DIVIS LABORATORIES | -1.9% | 5.5% | 60.6% |
MANKIND PHARMA | -1.2% | -4.8% | 36.6% |
TORRENT PHARMACEUTICALS | -0.2% | 4.6% | 57.8% |
LUPIN | 3.1% | -2.2% | 68.7% |
FUNDAMENTAL ANALYSIS OF SAMRAT PHARMACHEM
 Y : Last Audited Annual/Yearly Data
TTM i.e. Trailing Twelve Months is calculated using last 4 quarterly data and is a good substitute to track last 4 Qtr Annual result before the subsequent year data is published and audited.
Learn More
VALUATION OF SAMRAT PHARMACHEM
 Ratio | Standalone | |
---|---|---|
P/E P/B P/S |
19.37
P/E Calculated based on Trailing Twelve Months (TTM) Earnings of Rs 6.47 Cr
[Latest Qtr - Sep2024 - Standalone Results ] 1.93
P/B Calculated based on Book Value of Rs 65.00 Cr
[Latest Year - Mar2024 - Standalone Results ] 0.42
P/S Calculated based on Trailing Twelve Months (TTM) Revenues of Rs 0.00 Cr
[Latest Qtr - Sep2024 - Standalone Results ] |
|
Financial Ratios → |
Model | Discount(-)/ Premium(+) |
---|---|
EV/EBIDTA EV/Sales Price/Sales |
-16% 51% 62% |
SHARE PRICE MOMENTUM OF SAMRAT PHARMACHEM
SAMRAT PHARMACHEM vs SENSEX
DEBT OF SAMRAT PHARMACHEM
Year | Debt/Equity ratio | |
---|---|---|
Standalone | Consolidated | |
2024 2023 2022 Avg_3yrs |
0.13 0.3 0.16 0.2 |
- - - - |
[Last Annual Data : Mar2024]
|
||
Financial Ratios → |
PLEDGED PROMOTER SHARES OF SAMRAT PHARMACHEM
Pledged Promoter Shares |
NA | |
---|---|---|
If less than 25% | Good |
|
If between 25% and 50% | Neutral | |
If greater than 50% | Bad | |
Shareholding Pattern → |
QTRLY RESULTS OF SAMRAT PHARMACHEM
Standalone | Q-o-Q | Y-o-Y |
---|---|---|
Revenue Op Profit Profit Before Tax Profit After Tax |
-13.18% 29.99% 24.84% 28.86% |
-12% 1347.84% 1384.39% 1507.94% |
QtrlyTrend |
4 | |
Latest Qtr: Sep2024 | ||
Quarterly Result Analysis → |
SAMRAT PHARMACHEM related INDICES
You may also like the below Video Courses
FAQ about SAMRAT PHARMACHEM
Is SAMRAT PHARMACHEM good for long term investment?
As on Dec 06,2024, the Fundamentals of SAMRAT PHARMACHEM look Average and hence you may wait for the results to improve to invest for long term ! See Financial Performance of SAMRAT PHARMACHEM . Please look at the other parameters such as Valuation, Price Momentum, News & Corporate Governance and/or consult an Investment Advisor before taking an investment decision!Is SAMRAT PHARMACHEM UnderValued or OverValued?
As on Dec 06,2024, SAMRAT PHARMACHEM is Over Valued based on the estimates of intrinsic value and hence may not be a good buying opportunity according to Share Valuation at this time!What is the Intrinsic Value of SAMRAT PHARMACHEM ?
As on Dec 06,2024, the Intrinsic Value of SAMRAT PHARMACHEM is Rs. 268.20 estimated based on Median of the 3 historical models.Fair Value [Median EV / EBIDTA Model] : Rs. 484.61
Fair Value [Median EV / Sales Model] : Rs. 268.20
Fair Value [Median Price / Sales Model] : Rs. 250.81
Estimated Median Fair Value of SAMRAT PHARMACHEM : Rs. 268.20
The fair value of any stock is always subjective and should, in no way, be taken as a recommendation to buy/sell the same.